130 related articles for article (PubMed ID: 22078049)
21. [Medical therapy of malignant melanoma].
Mini E; Periti P
Ann Ital Chir; 1989; 60(4):257-63. PubMed ID: 2699710
[No Abstract] [Full Text] [Related]
22. [Late gastric metastasis from cutaneous melanoma].
Ruiz-Cuesta P; Hervás-Molina AJ; Villar-Pastor CM; Jurado-García J; Barrera-Baena P
Gastroenterol Hepatol; 2014 Dec; 37(10):564-5. PubMed ID: 24679375
[No Abstract] [Full Text] [Related]
23. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
25. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
[No Abstract] [Full Text] [Related]
26. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
[TBL] [Abstract][Full Text] [Related]
27. Nodular melanoma: review and report of a digital case.
Page JC
J Am Podiatry Assoc; 1981 Oct; 71(10):571-4. PubMed ID: 7288077
[No Abstract] [Full Text] [Related]
28. [Combined immuno-chemotherapy of malignant melanoma: epidemiological elements].
Jacquillat C; Banzet P; Maral J; Civatte J; Puissant A; Israel L; Chastang C; Cottenot F
Chirurgie; 1978 Nov; 104(10):973-7. PubMed ID: 747951
[No Abstract] [Full Text] [Related]
29. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
Korting HC; Strasser S; Konz B
Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
[TBL] [Abstract][Full Text] [Related]
30. [Malignant melanoma and its treatment].
Luther U; Dichmann S; Norgauer J
Med Monatsschr Pharm; 2001 Nov; 24(11):356-61. PubMed ID: 11727297
[No Abstract] [Full Text] [Related]
31. Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine.
Busch C; Geisler J; Knappskog S; Lillehaug JR; Lønning PE
J Invest Dermatol; 2010 Oct; 130(10):2514-6. PubMed ID: 20505745
[No Abstract] [Full Text] [Related]
32. Phase III adjuvant studies in operable malignant melanoma (review).
Lejeune FJ
Anticancer Res; 1987; 7(4B):701-5. PubMed ID: 3314671
[TBL] [Abstract][Full Text] [Related]
33. [Therapy and prognosis of malignant melanoma of the skin].
Braun-Falco O; Landthaler M; Hölzel D; Konz B; Schmoeckel C
Dtsch Med Wochenschr; 1986 Nov; 111(46):1750-6. PubMed ID: 3780438
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy for cutaneous melanoma.
Nathan FE; Mastrangelo MJ
Semin Oncol; 1995 Dec; 22(6):647-61. PubMed ID: 8539640
[No Abstract] [Full Text] [Related]
35. [Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations].
Négrier S; Saiag P; Guillot B; Verola O; Avril MF; Bailly C; Cupissol D; Dalac S; Danino A; Dreno B; Grob JJ; Leccia MT; Renaud-Vilmer C; Bosquet L; ;
Ann Dermatol Venereol; 2005 Dec; 132(12 Pt 2):10S3-10S85. PubMed ID: 16521904
[No Abstract] [Full Text] [Related]
36. [Clinical trials of supplementary chemotherapy in cases of malignant melanoma of the skin with unfavorable prognosis after surgical treatment].
Dobrek Z
Wiad Lek; 1987 Feb; 40(4):237-41. PubMed ID: 3617746
[No Abstract] [Full Text] [Related]
37. Case report: squamous cell carcinoma of the skin in both palms, axillary node, donor skin graft site and both soles--associated hyperkeratosis and porokeratosis.
Abadir R; Zurowski S
Br J Radiol; 1994 May; 67(797):507-10. PubMed ID: 8193903
[TBL] [Abstract][Full Text] [Related]
38. Combined modality therapy of malignant melanoma.
Hersh EM; Gutterman JU; McBride CM
World J Surg; 1979 Jul; 3(3):329-43. PubMed ID: 382647
[No Abstract] [Full Text] [Related]
39. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
[No Abstract] [Full Text] [Related]
40. [The present status of the multidisciplinary treatment of malignant melanoma].
Ishihara K; Hayasaka K; Ikegawa S; Kageshita T
Gan No Rinsho; 1985 Jul; 31(9 Suppl):1073-8. PubMed ID: 4057571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
